Subacute CNS Demyelination after Treatment with Immune Checkpoint Inhibitors
2021 ◽
pp. 10.1212/CPJ.0000000000001069
Keyword(s):
Immune checkpoints are molecules on the surface of leucocytes which modulate the amplitude of immune responses. Monoclonal antibodies blocking these molecules are known as immune checkpoints inhibitors (ICIs) and have been shown to unleash anti- tumour immunity and mediate durable cancer regressions. ICIs include ipilimumab which blocks the cytotoxic T-lymphocyte antigen-4 (CTLA-4), nivolumab and pembrolizumab which are both against the programmed cell death protein 1 (PD-1)1. The clinical use of these ICIs has led to significantly improved survival in patients with a variety of solid malignancies including melanoma.
2020 ◽
Vol 105
(5)
◽
pp. 1581-1588
◽
2020 ◽
Vol 20
(7)
◽
pp. 768-776
◽
2019 ◽
Vol 11
(4)
◽
pp. 225-236
◽
2017 ◽
Vol 103
(2)
◽
pp. 365-369
◽